BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25976565)

  • 21. Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker.
    van der Weerd NC; Grooteman MP; Nubé MJ; ter Wee PM; Swinkels DW; Gaillard CA
    Neth J Med; 2015 Mar; 73(3):108-18. PubMed ID: 25852110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron Status and Inflammation in Early Stages of Chronic Kidney Disease.
    Łukaszyk E; Łukaszyk M; Koc-Żórawska E; Tobolczyk J; Bodzenta-Łukaszyk A; Małyszko J
    Kidney Blood Press Res; 2015; 40(4):366-73. PubMed ID: 26160488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis.
    Arnold J; Sangwaiya A; Bhatkal B; Geoghegan F; Busbridge M
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):425-9. PubMed ID: 19262400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
    El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
    Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease.
    Niihata K; Tomosugi N; Uehata T; Shoji T; Mitsumoto K; Shimizu M; Kawabata H; Sakaguchi Y; Suzuki A; Hayashi T; Okada N; Isaka Y; Rakugi H; Tsubakihara Y
    Nephrol Dial Transplant; 2012 Dec; 27(12):4378-85; discussion 4384-5. PubMed ID: 22833619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron status in patients with chronic heart failure.
    Jankowska EA; Malyszko J; Ardehali H; Koc-Zorawska E; Banasiak W; von Haehling S; Macdougall IC; Weiss G; McMurray JJ; Anker SD; Gheorghiade M; Ponikowski P
    Eur Heart J; 2013 Mar; 34(11):827-34. PubMed ID: 23178646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepcidin, iron indices and bone mineral metabolism in non-dialysis chronic kidney disease.
    Min HK; Sung SA; Oh YK; Kim YH; Chung W; Park SK; Ahn C; Lee SW
    Nephrol Dial Transplant; 2020 Jan; 35(1):147-154. PubMed ID: 30053139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepcidin and iron metabolism disorders in patients with chronic kidney disease.
    Jelić M; Cvetković T; Djordjević V; Damnjanovć G; Vlahović P; Kocić G; Djindjić N; Jovović B; Antić A
    Vojnosanit Pregl; 2013 Apr; 70(4):368-73. PubMed ID: 23700940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease.
    Farag NM; Mousa M; Elsayed E; Ismeil A
    Ital J Pediatr; 2023 Aug; 49(1):106. PubMed ID: 37649102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease.
    Samouilidou E; Pantelias K; Petras D; Tsirpanlis G; Bakirtzi J; Chatzivasileiou G; Tzanatos H; Grapsa E
    Ther Apher Dial; 2014 Jun; 18(3):279-83. PubMed ID: 24119290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia.
    Jacober ML; Mamoni RL; Lima CS; Dos Anjos BL; Grotto HZ
    Med Oncol; 2007; 24(3):323-9. PubMed ID: 17873309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pro-hepcidin, its relation with indicators of iron metabolism and of inflammation in patients hemodialyzed treated or not with recombinant erythropoietin].
    Barrios Y; Espinoza M; Barón MA
    Nutr Hosp; 2010; 25(4):555-60. PubMed ID: 20694291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adolescent life-event stress in boys is associated with elevated IL-6 and hepcidin but not hypoferremia.
    Augustine LF; Nair KM; Rao SF; Rao MV; Ravinder P; Balakrishna N; Laxmaiah A; Vazir S
    J Am Coll Nutr; 2014; 33(5):354-62. PubMed ID: 25302670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection.
    de Mast Q; van Dongen-Lases EC; Swinkels DW; Nieman AE; Roestenberg M; Druilhe P; Arens TA; Luty AJ; Hermsen CC; Sauerwein RW; van der Ven AJ
    Br J Haematol; 2009 Jun; 145(5):657-64. PubMed ID: 19344417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease.
    Basseri RJ; Nemeth E; Vassilaki ME; Basseri B; Enayati P; Shaye O; Bourikas LA; Ganz T; Papadakis KA
    J Crohns Colitis; 2013 Sep; 7(8):e286-91. PubMed ID: 23219355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 3-marker index improves the identification of iron disorders in CKD anaemia.
    Mercadal L; Metzger M; Haymann JP; Thervet E; Boffa JJ; Flamant M; Vrtovsnik F; Gauci C; Froissart M; Stengel B;
    PLoS One; 2014; 9(2):e84144. PubMed ID: 24586229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum hepcidin levels are related to serum markers for iron metabolism and fibrosis stage in patients with chronic hepatitis B: A cross-sectional study.
    Çam H; Yılmaz N
    Arab J Gastroenterol; 2020 Jun; 21(2):85-90. PubMed ID: 32423859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
    Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between ferritin, high sensitivity C-reactive protein (hsCRP) and relative abundance of Hepcidin mRNA with the risk of type 2 diabetes in obese subjects.
    Andrews Guzmán M; Arredondo Olguín M
    Nutr Hosp; 2014 Sep; 30(3):577-84. PubMed ID: 25238834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.